Child Dies from Contaminated Coldrif Cough Syrup
Analysis based on 9 articles · First reported Feb 02, 2026 · Last updated Feb 03, 2026
The event highlights significant regulatory risks and reputational damage for pharmaceutical companies involved in manufacturing contaminated products. It underscores the importance of stringent quality control and regulatory oversight in the pharmaceutical industry, potentially leading to increased scrutiny and stricter regulations.
A four-year-old boy, Harsh, from Betul district, India===Madhya Pradesh, died at All India Institute of Medical Sciences, Nagpur, after being in a coma for over four months. His critical illness was allegedly caused by consuming Coldrif cough syrup, which was later found to contain diethylene glycol, a toxic chemical causing kidney failure. This incident is part of a larger tragedy where at least 24 children in India===Madhya Pradesh died from consuming the same contaminated syrup. Investigations led to the arrest of S. Ranganathan, the owner of Sresan Pharmaceuticals, the manufacturer, and Praveen Soni, a government doctor who recommended the syrup. The India===Madhya Pradesh government banned the syrup's sale, and the India===Drugs Controller General of India and India===Tamil Nadu Directorate of Drug Control conducted probes, confirming the syrup's adulteration.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard